Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Accro Raises $50 Million for Regulated Cell Death Drug Candidates

publication date: Jan 5, 2022

Accro Bioscience (Suzhou) raised more than $50 million in an oversubscribed Series B round to develop products based on the molecular mechanism of regulated cell death. Its portfolio of China Class 1.1 candidates include products for inflammatory, autoimmune and cancer indications. The company's research focuses on necroptosis, pyroptosis and ferroptosis, which are associated with major human diseases. The B round was led by Hongtai Aplus. Also participating were South China Venture apital, Shenzhen Capital Group and Suzhou Oriza Holdings.  More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital